{"id":386654,"date":"2020-11-23T08:03:37","date_gmt":"2020-11-23T13:03:37","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386654"},"modified":"2020-11-23T08:03:37","modified_gmt":"2020-11-23T13:03:37","slug":"recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/","title":{"rendered":"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SYDNEY, Australia, Nov.  23, 2020  (GLOBE NEWSWIRE) &#8212; Recce Pharmaceuticals Ltd (<strong>ASX: RCE<\/strong>), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled <em>\u201cAnti-virus Agent and Method for Treatment of Viral Infection\u201d<\/em>, furthering marketing and manufacturing monopolies to February 2037.<\/p>\n<p align=\"left\">\u201cRecce\u2019s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us,\u201d said Chief Executive Officer, James Graham. \u201cAt now 31 granted patents across three wholly-owned patent families, our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens.\u201d<\/p>\n<p align=\"left\">Japan Patent Office granted claims relate to RECCE<sup>\u00ae<\/sup> 327 (R327) and new anti-viral formulation RECCE<sup>\u00ae<\/sup> 529 (R529), most notably:<\/p>\n<ul type=\"disc\">\n<li>Composition\/method of manufacture of RECCE<sup>\u00ae<\/sup> anti-infectives<\/li>\n<li>Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and coronaviruses, influenza viruses, HIV, hepatitis, Ross River and Herpes viruses<\/li>\n<li>Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications <\/li>\n<\/ul>\n<p align=\"left\">Japan is the second largest pharmaceutical market in the world<sup>1<\/sup> with the unmet medical need from infections caused by lipid enveloped or coated viruses representing millions of potential patients Japan country alone. Patent Family 3 applications in other major pharmaceutical markets around the world are in their advanced stages of independent patent reviews.<\/p>\n<p>__________________________________<\/p>\n<p>\n        <sup>1<\/sup>\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-gDv3nO4FUGW11KlP_N6s6JDr0OuQukWNNqUsJSTMfUi6EPvW9QHlixYxiVqe-Z_6AiAKa_RyoXBNzQbgNYlDGjqLicpww-8yQXEDeA9-UWV_8zELTCoGKTtgt7Tiz5NT-c2reFdI7UYR7gddwz5mf1NTkqZHgrl90SStIIi42LWCApy1K9944gynl0kgJkMGxtXO8f8VrI0uqh5bq-e-CALedNfczrUuuASgeC58FRIKhXaMvWnyjWSG6M4-YZ4A_AIRRpsgkVNZ6nr6ExWqHzA3X6yyCEw9TXuilUSRlctUYlJM2-sjsgTFr39HGtdNXLyW7ICpHE1XgB0QyXmcw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.worldatlas.com\/articles\/countries-with-the-biggest-global-pharmaceutical-markets-in-the-world.html<\/a><\/p>\n<p>\n        \n      <\/p>\n<p>\n        <strong>About Recce Pharmaceuticals Ltd<\/strong><\/p>\n<p>Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialization of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.<\/p>\n<p align=\"justify\">Recce\u2019s anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE<sup>\u00ae<\/sup> 327 and RECCE<sup>\u00ae<\/sup> 435, and RECCE<sup>\u00ae<\/sup> 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.<\/p>\n<p align=\"justify\">Patented lead candidate RECCE<sup>\u00ae<\/sup> 327 has been developed for the treatment of blood infections and sepsis derived from <em>E. coli<\/em> and <em>S. aureus<\/em> bacteria \u2013 including their superbug forms. Recce\u2019s new antibiotic compound, RECCE<sup>\u00ae<\/sup> 435, has been formulated for oral use.<\/p>\n<p align=\"justify\">The FDA has awarded RECCE<sup>\u00ae<\/sup> 327 <em>Qualified Infectious Disease Product<\/em> designation under the <em>Generating Antibiotic Initiatives Now<\/em> (GAIN) Act \u2013 labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.<\/p>\n<p align=\"justify\">Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce\u2019s anti-infective pipeline seeks to exploit the unique capabilities of RECCE<sup>\u00ae<\/sup> technologies targeting synergistic, unmet medical needs.<\/p>\n<p align=\"justify\">\n        <strong>Corporate Contact<\/strong><br \/>\n        <br \/>James Graham<br \/>Recce Pharmaceuticals Ltd<br \/>+61 (02) 8075 4585<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DoXMv3Ql07e7MRe1F2LFNq8ygVveaXKIJSyXmuESdedygJhacQYiXlsoAfEjH6hyF-VY_wFtBWDVkI97LHJrkEkem5vnfJWVbr8BIBTbQJs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">James.graham@recce.com.au<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media and Investor Relations (AU)<\/strong><br \/>\n        <br \/>Andrew Geddes <br \/>CityPR<br \/>+61 (02) 9267 4511<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3O4h_8pddmFwnunu58I34kOcUp4v4Zs9sNjwxEGmq_ltxWwghEHFW851oWT2eboI756giC3U-KLNf_X5rfs1ZpJKw5SvKfkBOHVIcRY7AmLqFd9APm5Oeaqd01uhtNc_xEv2U0MVfTMUWUdmWomNHw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ageddes@citypublicrelations.com.au<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media and Investor Relations (USA)<\/strong><br \/>\n        <br \/>Meredith Sosulski, Ph.D.<br \/>LifeSci Communications<br \/>+1 929 469 3851<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HZcllDePLA3CxU5zg5gha0Ab1L3xkfu-VT1wvP-dbbtwwFyOz2pkj1u2I4Pcol7aD-VILlXk71BDD17mf1RL8C6wMsSKJKGaOMr1VZLrH1Hsri3w6BBDICYzmJBkyHBM\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">msosulski@lifescicomms.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5b09c056-e816-4302-9910-59430345c3a4\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SYDNEY, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled \u201cAnti-virus Agent and Method for Treatment of Viral Infection\u201d, furthering marketing and manufacturing monopolies to February 2037. \u201cRecce\u2019s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us,\u201d said Chief Executive Officer, James Graham. \u201cAt now 31 granted patents across three wholly-owned patent families, our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens.\u201d Japan Patent Office granted claims relate to RECCE\u00ae 327 (R327) and new anti-viral formulation RECCE\u00ae &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386654","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SYDNEY, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled \u201cAnti-virus Agent and Method for Treatment of Viral Infection\u201d, furthering marketing and manufacturing monopolies to February 2037. \u201cRecce\u2019s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us,\u201d said Chief Executive Officer, James Graham. \u201cAt now 31 granted patents across three wholly-owned patent families, our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens.\u201d Japan Patent Office granted claims relate to RECCE\u00ae 327 (R327) and new anti-viral formulation RECCE\u00ae &hellip; Continue reading &quot;Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T13:03:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives\",\"datePublished\":\"2020-11-23T13:03:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/\"},\"wordCount\":445,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/\",\"name\":\"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==\",\"datePublished\":\"2020-11-23T13:03:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/","og_locale":"en_US","og_type":"article","og_title":"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives - Market Newsdesk","og_description":"SYDNEY, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled \u201cAnti-virus Agent and Method for Treatment of Viral Infection\u201d, furthering marketing and manufacturing monopolies to February 2037. \u201cRecce\u2019s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us,\u201d said Chief Executive Officer, James Graham. \u201cAt now 31 granted patents across three wholly-owned patent families, our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens.\u201d Japan Patent Office granted claims relate to RECCE\u00ae 327 (R327) and new anti-viral formulation RECCE\u00ae &hellip; Continue reading \"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T13:03:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives","datePublished":"2020-11-23T13:03:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/"},"wordCount":445,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/","name":"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==","datePublished":"2020-11-23T13:03:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDU1OCMzODM5Mjk2IzUwMDA3MTAwNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/recce-pharmaceuticals-announces-anti-viral-patent-granted-in-japan-for-recce-anti-infectives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE\u00ae Anti-Infectives"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386654"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386654\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}